Blujepa Shortage Update: What Patients Need to Know in 2026

Blujepa Shortage Update: What Patients Need to Know in 2026

If you've been searching for Blujepa (Gepotidacin) and coming up empty, you might assume the drug is in shortage. The situation is more nuanced than that. Here's everything you need to know about Blujepa availability in 2026.

Is Blujepa Currently in Shortage?

No. As of February 2026, Blujepa is not listed on the FDA's Drug Shortages database. GSK, the sole manufacturer, continues to produce and distribute the medication.

However, "not in shortage" doesn't mean "easy to find." Many patients are still struggling to locate Blujepa at their local pharmacy. The issue isn't a supply problem at the manufacturing level — it's a distribution and stocking problem at the pharmacy level.

Why Is Blujepa Hard to Find?

Several factors contribute to difficulty finding Blujepa in 2026:

New Drug, Limited Awareness

Blujepa was approved by the FDA in March 2025 — less than a year ago. It's a first-in-class antibiotic (triazaacenaphthylene topoisomerase inhibitor), and many pharmacists and prescribers are still becoming familiar with it. Pharmacies don't typically stock medications until they see consistent demand.

Single Manufacturer

GSK is the only company producing Blujepa. There's no generic version and no authorized generic. This means the entire supply chain depends on one manufacturer, which can lead to spotty distribution — particularly at smaller pharmacies that order less frequently.

High Cost Limits Inventory

At $400-$600 per course without insurance, Blujepa is expensive inventory for pharmacies to carry. If a pharmacy stocks it and it doesn't sell, they're sitting on a costly product. Many pharmacies prefer to order it on demand rather than keep it on the shelf.

Insurance Barriers

Many insurance plans require prior authorization before covering Blujepa. Some require step therapy, meaning you must try cheaper antibiotics like Nitrofurantoin or Bactrim first. These requirements slow down the process and can make pharmacies hesitant to fill the prescription until coverage is confirmed.

How Much Does Blujepa Cost in 2026?

Here's what you can expect to pay:

• Without insurance: $400-$600 for a 5-day UTI course (ten 750 mg tablets)
• With commercial insurance: Copays vary widely, from $30-$150 depending on your plan and formulary tier
• Gonorrhea dosing (two doses of 3,000 mg): Higher cost due to more tablets needed (sixteen 750 mg tablets total)

For tips on reducing your out-of-pocket costs, see our guide on how to save money on Blujepa.

Are There New Treatment Options in 2026?

The biggest update for Blujepa in 2026 is the expanded indication for gonorrhea, which was approved in December 2025. This means Blujepa is now an oral treatment option for uncomplicated urogenital gonorrhea — a significant development because most gonorrhea treatments require an injection.

This expanded use may increase demand for Blujepa and, over time, lead to better pharmacy stocking as more prescribers become aware of the drug.

For alternative treatments, there are several established options. Read our full guide on alternatives to Blujepa.

How to Find Blujepa in Stock

If you need Blujepa now, here are your best options:

1. Use Medfinder — Search for pharmacies near you that currently have Blujepa in stock
2. Try independent pharmacies — They often have more flexibility to order specialty medications quickly
3. Ask your doctor to call ahead — Your prescriber's office can confirm availability before sending the prescription
4. Consider mail-order — Insurance mail-order pharmacies often stock a wider range of brand-name drugs
5. Check hospital outpatient pharmacies — Academic medical centers are more likely to carry newer antibiotics

For a complete walkthrough, see our guide on how to find Blujepa in stock near you.

What to Do If You Can't Wait

Urinary tract infections and gonorrhea need prompt treatment. If you can't find Blujepa quickly, contact your doctor right away to discuss alternatives. Do not delay treatment while waiting for a pharmacy to stock Blujepa.

Common alternatives for UTIs include Nitrofurantoin (Macrobid) at $10-$30 per course and Trimethoprim-Sulfamethoxazole (Bactrim) at $5-$20 per course. For gonorrhea, Ceftriaxone injection remains the standard of care and is widely available.

Final Thoughts

Blujepa is not in shortage in 2026, but it can still be challenging to find due to its newness, single-manufacturer status, and high cost. The most important thing is not to delay treatment — use Medfinder to find it quickly, or talk to your doctor about alternatives if time is critical.

As awareness of Blujepa grows and more prescribers adopt it — especially for the new gonorrhea indication — pharmacy stocking should improve throughout 2026.